Cargando…

Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371019/ https://www.ncbi.nlm.nih.gov/pubmed/32690666 http://dx.doi.org/10.1136/jitc-2019-000437corr1

Ejemplares similares

Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
por: Shen, Lin, et al.
Publicado: (2020)

Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study
por: Thein, Kyaw Zin, et al.
Publicado: (2021)

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial
por: Friedlander, Michael, et al.
Publicado: (2023)

Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial
por: Ren, Zhenggang, et al.
Publicado: (2022)

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
por: Desai, Jayesh, et al.
Publicado: (2020)

Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study
por: Bachy, Emmanuel, et al.
Publicado: (2023)

Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial
por: Qin, Shukui, et al.
Publicado: (2022)

Correction: Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines in Chinese Patients: A Pivotal, Phase 3, Randomized, Double-Blind and Open-Label Phase Study
por: Wu, Yan, et al.
Publicado: (2023)

Model‐based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors
por: Budha, Nageshwar, et al.
Publicado: (2022)

Correction to: Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study
por: Uemura, Hiroji, et al.
Publicado: (2020)

Correction: Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study
Publicado: (2022)

AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors
por: Frentzas, Sophia, et al.
Publicado: (2023)

Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial
por: Cao, Yanshuo, et al.
Publicado: (2022)

Phase 1 study on docetaxel and ifosfamide in patients with advanced solid tumours
Publicado: (1998)

Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
por: Wang-Gillam, Andrea, et al.
Publicado: (2023)

Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study
por: Thein, Kyaw Z., et al.
Publicado: (2021)

Co-enrichment of CD8-positive T cells and macrophages is associated with clinical benefit of tislelizumab in solid tumors
por: Ye, Dingwei, et al.
Publicado: (2023)

Correction: Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
Publicado: (2020)

Correction: Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan
por: Tajiri, Hitoshi, et al.
Publicado: (2022)

A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours
por: Desai, Jayesh, et al.
Publicado: (2023)

Phase I, multicenter, open‐label, dose‐escalation study of sonidegib in Asian patients with advanced solid tumors
por: Minami, Hironobu, et al.
Publicado: (2016)

A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors
por: Richardson, Gary Edward, et al.
Publicado: (2023)

Correction to: Safety and efficacy of azilsartan in paediatric patients with hypertension: a phase 3, single-arm, open-label, prospective study
por: Ito, Shuichi, et al.
Publicado: (2022)

Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
por: Annunziata, Christina M., et al.
Publicado: (2012)

Correction: A randomized, open-label, parallel, multi-center Phase IV study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk Asian patients with hypercholesterolemia
por: Kim, Ji Bak, et al.
Publicado: (2021)

Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215)
por: Zhao, Wensi, et al.
Publicado: (2023)

A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors
por: Rodon, Jordi, et al.
Publicado: (2018)

An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors
por: Taylor, Kirsty, et al.
Publicado: (2020)

Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors
por: Gordon, Michael S., et al.
Publicado: (2021)

Correction: Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial
Publicado: (2023)

An Open‐label Phase 1 Dose‐escalation Clinical Trial of a Single Intravenous Administration of Gemcitabine in Dogs with Advanced Solid Tumors
por: Marconato, L., et al.
Publicado: (2015)

A phase 1, open-label, drug–drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors
por: Liao, Mingxiang, et al.
Publicado: (2021)

Correction to: Solid tumor size for prediction of recurrence in large and giant non-functioning pituitary adenomas
por: Ko, Ching-Chung, et al.
Publicado: (2021)

Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody
por: Zhang, Lin, et al.
Publicado: (2022)

Pharmacokinetics, Safety, and Preliminary Efficacy of Oral Trifluridine/Tipiracil in Chinese Patients with Solid Tumors: A Phase 1b, Open-Label Study
por: Wang, Xicheng, et al.
Publicado: (2020)

The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma
por: Wang, Zhixin, et al.
Publicado: (2022)

Correction: Multicentre, randomised, open-label, non-inferiority trial comparing the effectiveness and safety of ductal lavage versus oral corticosteroids for idiopathic granulomatous mastitis: a study protocol
Publicado: (2022)

Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours
por: Lickliter, Jason D., et al.
Publicado: (2021)

Correction:Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study
por: Frank, Samuel
Publicado: (2011)

Correction to: Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study
por: Iwanami, Akira, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i03t5ud7dq94i5qief93a5mqmk